Ad5-EBOV
AXP000173.1 · Vaccine
- Platform
- human adenovirus 5 (non-replicating)
- Targets
- Zaire ebolavirus GP
- Originator
- Beijing Institute of Biotechnology
- Sponsor
- CanSino Biologics
Names
Virus
- Role
- Vaccine vector
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5
- Replication
- non replicating
- Modifications
- replication-defective human adenovirus type 5 encoding Ebola virus glycoprotein
- Transgenes
- Zaire ebolavirus glycoprotein
- Route
- intramuscular
- Source
- evidence
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| NMPA | CN | 2017 | approved | Prevention of Ebola virus disease (emergency use stockpile licence) | source |
Clinical trials (3)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT02533791 | A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization | Completed | Phase 1 | 2015-07 | 2015-09 | 110 | Ebola Virus Disease |
| NCT02401373 | A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China. | Completed | Phase 1 | 2015-03 | 2015-07 | 61 | Ebola Virus Disease |
| NCT02326194 | A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults. | Completed | Phase 1 | 2014-12 | 2015-02 | 120 | Ebola Virus Disease |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 32213108 | Potent neutralizing monoclonal antibodies against Ebola virus isolated from vaccinated donors. | mAbs | 2020 | name in abstract: Ad5-EBOV |
| PMID 28017642 | Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. | The Lancet. Global health | 2017 | cited by trial NCT02326194 |
| PMID 28362208 | The early-onset febrile reaction following vaccination and associated factors: An exploratory sub-study based on the Ebola vaccine clinical trial. | Human vaccines & immunotherapeutics | 2017 | name in abstract: Ad5-EBOV |
| PMID 28708962 | Open-label phase I clinical trial of Ad5-EBOV in Africans in China. | Human vaccines & immunotherapeutics | 2017 | cited by trial NCT02401373 |
| PMID 25817373 | Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. | Lancet (London, England) | 2015 | cited by trial NCT02326194 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 38745762 | A causal multiomics study discriminates the early immune features of Ad5-vectored Ebola vaccine recipients. | Innovation (Cambridge (Mass.)) | 2024 | name in abstract: Ad5-EBOV |
| PMID 36119119 | Comparative immunogenicity analysis of intradermal versus intramuscular immunization with a recombinant human adenovirus type 5 vaccine against Ebola virus. | Frontiers in immunology | 2022 | name in abstract: Ad5-EBOV |
| PMID 32164743 | Challenges and opportunities for China entering global research and development for emerging infectious diseases: a case study from Ebola experience. | Infectious diseases of poverty | 2020 | name in abstract: Ad5-EBOV |
| PMID 31272985 | Effects of vaccines in protecting against Ebola virus disease: protocol for a systematic review. | BMJ open | 2019 | name in abstract: Ad5-EBOV |
| PMID 28795602 | Immunogenicity of Recombinant Adenovirus Type 5 Vector-Based Ebola Vaccine Expressing Glycoprotein from the 2014 Epidemic Strain in Mice. | Human gene therapy | 2018 | name in abstract: Ad5-EBOV |
| PMID 30381976 | Establishing China's National Standard for the Recombinant Adenovirus Type 5 Vector-Based Ebola Vaccine (Ad5-EBOV) Virus Titer. | Human gene therapy. Clinical development | 2018 | name in title: Ad5-EBOV |
Notes
Recombinant replication-defective human adenovirus type 5 carrying the Ebola virus glycoprotein, developed with the Beijing Institute of Biotechnology; licensed in China in 2017, the country's first Ebola vaccine. Exact approval date, agency name and the Ebola strain used for the glycoprotein were not verified from the sources read.
How to cite
Ad5-EBOV (AXP000173.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000173.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.